1020 First Avenue
King of Prussia
About CSL Behring
As the third largest global biotechnology company with employees in more than 35 countries, CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research.
CSL Behring's dynamic environment fosters innovation and attracts the best and brightest who share a commitment to helping save lives. People here are free to live their Promising FUTURES where they can fulfill their individual career aspirations and realize their potential.
CSL Behring is committed to diversity and inclusion, both of which underpin our Values of patient focus, innovation, collaboration, integrity and superior performance. We believe that by harnessing and honoring the unique capabilities, experiences and perspectives of our people, we are better able to serve our patients.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries.
For more information visit www.cslbehring.com. Help us deliver on our promise to save lives and protect the health of people around the world. Promising FUTURES start at CSL Behring!
Stock Symbol: CSL
Stock Exchange: Australian Securities Exchange
An overview of the CSL Behring Fermentation Facility at Penn State
282 articles with CSL Behring
The filing to the U.S. District Court District of New Jersey, dated December 31st, 2020, states that the materials include compound data, strategic plans related to translational and biomarker data, therapeutic program reviews, abstract publications, plans for Congressional presentations, drug mo...
1/5/2021The new year is here and the biotech job market is hot! A new year, a new you, a new job?
New Harris Poll Survey Finds Vast Majority of People Living with Hereditary Angioedema (HAE) Value Efficacy and Specific Correction of C1-INH Deficiency When Choosing an HAE Therapy
CSL Behring, a global biotherapeutics leader, announced survey results showing that a vast majority of HAE patients say it's important their preventive therapy specifically corrects C1 esterase inhibitor deficiency.
Urban League, CSL Behring Partner to Address Community Needs including Public Health, Workforce Diversity, Leadership Development
Global biotherapeutics leader CSL Behring announced a community partnership with six Urban League affiliates across the U.S., starting with the Urban League of Philadelphia.
CSL Behring To Present New Real-World Data on Outcomes Following Acute Coronary Syndrome at the American Heart Association (AHA) Virtual Scientific Sessions 2020
Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio with prominent cardiovascular thought leaders to discuss emerging treatment targets
CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients
The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) during the high-risk 90-day period following a heart attack
Forbes magazine has named global biotechnology leader CSL Limited to its World's Best Employers 2020 list.
Diversity is good for our people, it’s good for our business and it’s good for our patients.
10/12/2020It was a moderately busy week for clinical trial news. Here’s a look.
At White House Roundtable, Plasma Industry Leader & CSL CEO Paul Perreault Urges People to Donate Plasma in the Fight Against COVID-19
On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit TheFightIsInUs.org.
- Five coagulation researchers named this year's recipients - Professor Heimburger Awards and ISTH Virtual Congress sponsorship showcase CSL Behring's commitment to hematology research
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
CSL Behring bolstered its growing gene therapy portfolio with the acquisition of global rights to uniQure’s gene therapy program for hemophilia B that has a price tag of up to $2 billion.
The University City Science Center announces the election of two new Board members, following the 2020 Annual Meeting of Shareholders held on June 19th: Yi Deng, Ph.D., Dean and Isaac L. Auerbach Professor in the College of Computing and Informatics at Drexel University, and Bill Mezzanotte, M.D., M.P.H., Executive Vice President, Head of Research and Development and Chief Medical Officer at CSL Behring.
6/15/2020It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever Virtual Summit June 14-19, 2020 . WFH is an
CSL Behring, a global biotherapeutics leader, announced results of a Phase 2 clinical trial for garadacimab, an investigational novel Factor XIIa-inhibitory monoclonal antibody in development as a preventive treatment in hereditary angioedema.
CSL Behring, based in King of Prussia, Pennsylvania, is acquiring Vancouver, British Columbia-based Vitaeris. The two companies inked a strategic partnership in 2017 to accelerate the development of Vitaeris’s clazakizumab. At that time, CLS Behring also had an option to acquire Vitaeris, the the...
CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases
Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA) [02-June-2020] SEATTLE and KING of PRUSSIA, Pa. , June 2, 2020 /PRNewswire/ -- Seattle Children's Research Institute, one of the top pediatric research institutio
CSL Behring has developed a number of strategies to address COVID-19, the disease caused by the novel coronavirus that originated in China and spread across the globe in a matter of months.